| ¿µ¹® | enzyme-linked immunoabsorbent assay | ÇÑ±Û | È¿¼Ò¸é¿ªÃøÁ¤¹ý |
|---|---|---|---|
| ¼³¸í | È¿¼Ò°áÇո鿪ÈíÂøÁ¦ °ËÁ¤¹ýÀ¸·Î ¹ø¿ªµÇ°í ÀÖ´Ù. ÀÌ ¹ýÀº Ç׿ø(¶Ç´Â Ç×ü)¿¡ ¾ËÄ®¸® Æ÷½ºÆÄŸ¾ÆÁ¦ ¶Ç´Â Æä¸£¿Á½Ãµð¾ÆÁ¦ µîÀÇ »ê¼Ò¸¦ °áÇÕ½ÃÄÑ µÎ°í ±× »ê¼ÒȰ¼ºÀ» ÁöÇ¥·Î »ï¾Æ Ç׿øÇ×ü¹ÝÀÀÀÇ Á¤µµ¸¦ ¾È ´ÙÀ½ ¿©±â¿¡¼ Ç׿ø(¶Ç´Â Ç×ü)ÀÇ ¾çÀ» ±¸ÇÏ´Â °ÍÀÌ´Ù. ÀÌ ¹ýÀÇ ÀÌÁ¡À¸·Î¼ °í°¨µµ, Á¶ÀÛÀÇ °£´ÜÇÔ ¹× ¹æ»ç¼±¸é¿ªÃøÁ¤¹ýó·³ ¹æ»ç¼º¹°ÁúÀ» »ç¿ëÇÏÁö ¾Ê¾Æµµ µÈ´Ù´Â Á¡À» µé ¼ö ÀÖ´Ù. È£¸£¸óÀ̳ª ¸é¿ª±Û·ÎºÒ¸°ÀÇ Á¤·®¹ýÀ¸·Î¼ ÀÀ¿ë µÇ°í ÀÖÀ¸¸ç ÃøÁ¤¿ë ŰƮµµ ½ÃÆÇµÇ°í ÀÌÀÖ´Ù. |
||
| IFA | idiopathic fibrosing alveolitis; immunofluorescence assay; immunofluorescent antibody; incomplete Fr... |
|---|---|
| LAI assay | Leukocyte Adherence Inhibition assay |
| ERA | electrical response activity; electroencephalic response audiometry; Electroshock Research Associati... |
| ACIF | anticomplement immunofluorescence |
| CLIF | cloning inhibitory factor; Crithidia luciliae immunofluorescence |
| DFA | Direct immunofluorescence assay |
|---|---|
| IIF | indirect immunofluorescence assay |
| ACIF | Anticomplement immunofluorescence |
| DIF | Direct Immunofluorescence |
| IF | Immunofluorescence |
| anticomplement immunofluorescence | A technique used to make certain indirect fluorescent antibody techniques more specific and sensitive. Here the fluorescent dye is conjugated to antibody directed at complement and then added to a complement-fixing complex of antigen and patient antibody. (05 Mar 2000) |
|---|---|
| avidin-biotin immunofluorescence | Holds promise for more sensitive and specific amplification of indirect fluorescent antibody procedures. Antibody to the patient's specific antibodies is labelled with biotin, a compound capable of specifically binding avidin in high concentrations. Fluorescent labelled avidin is then added and fluorescent microscopy is used to detect the presence of the complexes. (05 Mar 2000) |
| micro-immunofluorescence | Several different substrates are arranged in specific locations on a single microscope slide well allowing a rapid, simultaneous indirect fluorescent antibody on each substrate. (05 Mar 2000) |
| immunofluorescence | <technique> A test or technique in which one or other component of an immunological reaction is made fluorescent by coupling with a fluorochrome such as fluorescein, phycoerythrin or rhodamine so that the occurrence of the reaction can be detected as a fluorescing antigen-antibody complex. Used in microscopy to localise small amounts of antigen or specific antibody. (18 Nov 1997) |
| immunofluorescence method | Any method in which a fluorescent-labelled antibody is used to detect the presence or determine the location of the corresponding antigen. (05 Mar 2000) |
| indirect immunofluorescence | <procedure> A method of immunofluorescence staining in which the first antibody, that is directed against the antigen to be localised, is used unlabelled and the location of the first antibody is then detected by use of a fluorescently labelled antiIgG (against IgGs of the species in which the first antibody was raised). The advantage is that there is some amplification and a well characterised goat antirabbit IgG antibody can, for example: be used against a scarce specific antibody raised in rabbits. The same technique can be used for ultrastructural localisation of the first antibody by substituting peroxidase or gold labelled second antibody. (18 Nov 1997) |
| acetyl reduction assay | <investigation> A technique for measuring the nitrogen fixation activity in photosynthetic organisms. It uses a flame ionisation detector and a gas chromatography apparatus to determine the reduction of acetylene to ethylene by the enzyme nitrogenase. (06 May 1997) |
| Ames assay | <procedure> One of a number of procedures used to test substances for likely ability to cause cancer that combines the use of animal tissue to generate active metabolites of the substance with a test for mutagenicity in bacteria. (18 Nov 1997) |
| antibiotic assay | <investigation> A test to determine how sensitive a bacterial or fungal strain is to arange of antibiotics bymeasuring the microbes' ability to grow in astandard dilution of each chemical. (09 Oct 1997) |
| assay | <procedure> The determination of the amount of a particular constituent of a mixture or of the biological or pharmacological potency of a drug. (10 May 1997) |
| bandshift assay | <investigation> An assay for proteins, such as transcription factors, that bind specific DNA sequences. A labelled oligonucleotide corresponding to the recognition sequence is incubated with an appropriate nuclear protein extract and run on a nondenaturing acrylamide gel. Oligonucleotides that have been bound by proteins are retarded relative to those that are unbound. (18 Nov 1997) |
| biological assay | <technique> Once a pharmaceutical protein is isolated from the cells in which it was grown, researchers perform tests to measure the protein's biological activity. It must maintain a certain minimal level of biological activity to be used for animal or clinical testing or, later, for market. Researchers also test to confirm that the isolated protein is identical to the desired protein. (21 Mar 1998) |
| radioimmunoprecipitation assay | Sensitive assay using radiolabelled antigens to detect specific antibodies in serum. The antigens are allowed to react with the serum and then precipitated using a special reagent such as protein a sepharose beads. The bound radiolabelled immunoprecipitate is then commonly analyzed by gel electrophoresis. Radioimmunoprecipitation assay (ripa) is often used as a confirmatory test for diagnosing the presence of HIV antibodies. (12 Dec 1998) |
| radioligand assay | <radiobiology> Quantitative determination of receptor (binding) proteins in body fluids or tissue using radioactively labelled binding reagents (e.g., antibodies, intracellular receptors, plasma binders). (12 Dec 1998) |
| radioreceptor assay | A competitive binding assay in which the binder is a membrane or tissue receptor rather than an antibody. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|